China Medical System Holdings (CMS; HKG: 0867) has entered into a licensing agreement with compatriot firm Atom Therapeutics, securing exclusive commercialization rights to ABP-671, a Category 1 chemical drug for gout and hyperuricemia, in mainland China, Hong Kong, and Macau. The financial specifics of the agreement were not disclosed.
ABP-671: A Potential Treatment for Gout and Hyperuricemia
ABP-671 is currently undergoing Phase IIb/III studies for gout in China and overseas. The drug works by reducing the reabsorption of uric acid by the kidneys through the inhibition of urate transporter 1 (URAT1). This mechanism of action has the potential to significantly impact the treatment landscape for gout and hyperuricemia, two conditions characterized by elevated levels of uric acid in the body.
Positive Results from Phase II Trials
The results of two concluded Phase II trials have demonstrated good efficacy and safety of ABP-671 under multiple doses. These positive outcomes support the advancement of ABP-671 into later stages of clinical development, with the potential to provide a new treatment option for patients suffering from gout and related conditions.-Fineline Info & Tech
